A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of CC-90011 in Subjects With Advanced Solid Tumors and Non-Hodgkin Lymphomas

Trial Profile

A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of CC-90011 in Subjects With Advanced Solid Tumors and Non-Hodgkin Lymphomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs CC 90011 (Primary)
  • Indications Diffuse large B cell lymphoma; Neuroendocrine carcinoma; Non-Hodgkin's lymphoma; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 Dec 2016 Planned number of patients changed from 70 to 115.
    • 08 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 30 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top